A federal advisory panel is slated to review Mesoblast Limited’s (MESO) Ryoncil, proposed for the treatment of steroid-refractory acute graft versus host disease in children, on August 13, 2020.Ryoncil is comprised of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor and is designed to be administered to patients in a series of intravenous infusions.Steroid-refractory acute graft versus host disease is a potentially life-threatening complication of an allogeneic bone marrow transplant for blood cancer. Incyte Corp.’s (INCY) Jakafi is the first and only FDA-approved treatment for patients with steroid-refractory acute graft-versus-host disease (GVHD).The FDA is expected to make a final decision on Ryoncil September 30, 2020. Although the regulatory agency usually follows the recommendations of its advisory committees, it is not required to do so.MESO closed Friday’s (Jul.24, 2020) trading at $12.49, up 1.38%.